Bruce C. Cozadd brings extensive experience in research and development, manufacturing and sales and marketing. After being inspired by the culture at ALZA where he started his career, Mr. Cozadd wanted to start a company where top talent can do their best and work inclusively as a team. It was under these ideals that Mr. Cozadd co-founded Jazz Pharmaceuticals Inc. in 2003.
Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on its Health Section Governing Board. Mr. Cozadd also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics and biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.
Paul L. Berns has developed a strong business acumen from his time in venture capital as well as industry expertise in biopharmaceuticals and biotechnology. Mr. Berns built and led three pharmaceutical companies, all of which were acquired by some of the sector’s leading companies. His long and successful career, including as a CEO, has allowed him to contribute significantly to the Company’s strategic visions since he began as a Jazz director in 2010.
He is Managing Director at ARCH, a venture capital firm, and Executive Chair of RBNC, a privately-held biopharmaceutical company, where he serves on the board of directors. He also currently serves as Chairman of the board of Epirium Bio, Inc., a clinical-stage, privately-held biopharmaceutical company, as well as on the board of directors of UNITY Biotechnology, Inc., a publicly-held biotechnology company. From March 2014 to June 2016, he served as the Chief Executive Officer and President of Anacor Pharmaceuticals, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. in June 2016. He also served as a member of the board of directors of Anacor Pharmaceuticals, Inc. from 2012 until 2016, including as Chairman of its board of directors from 2013 until 2016. From September 2012 to March 2014, he was a self-employed consultant to the pharmaceutical industry. From March 2006 to September 2012, he served as President and Chief Executive Officer, and as a member of the board of directors, of Allos Therapeutics, Inc., a pharmaceutical company acquired by Spectrum Pharmaceuticals, Inc. From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns previously served on the boards of directors of Menlo Therapeutics Inc. from November 2017 to March 2020, Cellectar Biosciences, Inc. (formerly Novelos Therapeutics, Inc.) from November 2013 to June 2016 and XenoPort, Inc. from 2005 to May 2016. Mr. Berns received a B.S. in Economics from the University of Wisconsin.
Jennifer E. Cook brings over 30 years of biopharmaceutical experience with significant C-suite, global product development and commercialization expertise, with a focus on transformative growth. After receiving her MBA from the University of California, Berkeley, Ms. Cook joined the team launching Herceptin, the first monoclonal antibody that blocks a cancer-causing protein. In 2016, Ms. Cook was recognized as Woman of the Year by the Healthcare Businesswoman's Association.
Ms. Cook was the Chief Executive Officer at GRAIL, Inc., a privately-held early cancer detection diagnostic company from January 2018 to June 2019. Prior to that, Ms. Cook worked at Roche Pharmaceuticals/Genentech for 25 years where she held a number of senior management positions covering the full lifecycle of product development and commercialization. From 2010 to 2013, she oversaw Genentech's U.S. Immunology and Ophthalmology Business Unit, and from 2013 to 2016, she led Roche's European commercial business. She also served as Roche's Global Head of Clinical Operations throughout 2017. Ms. Cook currently serves as non-executive director on the boards of two publicly-held biotechnology companies, Denali Therapeutics Inc., and BridgeBio Pharma, Inc. She also serves on the boards of two privately-held biotechnology companies, Ambys Medicines, Inc. and Gyroscope Therapeutics Limited. Ms. Cook received a B.A. in human biology and a M.S. in biology from Stanford University and an M.B.A. from the Haas School of Business at University of California, Berkeley.
Patrick G. Enright brings extensive experience both managing life-sciences and biopharma companies and investing in them. As a venture capital investor and someone who has worked in the pharmaceutical industry, Mr. Enright brings both operating and financial expertise.
Mr. Enright has served as a member of our board of directors since July 2009. Since 2006, Mr. Enright has served as Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves as the Chairman of Aptinyx Inc., clinical-stage biopharmaceutical company, as well as a board member of several private companies. Selected prior public company board memberships include Aimmune Therapeutics, Inc., (acquired by Nestlé Health Science in October 2020), Codexis, Inc., Corcept Therapeutics, Inc., Esperion Therapeutics, Inc., Horizon Pharma plc and Threshold Pharmaceuticals, Inc. Mr. Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of the University of Pennsylvania.
Peter Gray brings over 30 years of experience in the pharmaceutical industry and pharmaceutical services. Mr. Gray earned a degree in law from Trinity College Dublin and qualified as a chartered accountant in 1981, and leveraged these qualifications to help turn his love of science and his belief in business into a long and successful career.
Mr. Gray has served as a member of our board of directors since May 2013 and was appointed as chairperson of our Audit Committee in April 2014. He is also a Chairman of two privately-held companies providing outsourced services to the biopharma industry and chairs a non-profit educational establishment. He served as Chairman of the board of directors of UDG Healthcare plc, an international provider of healthcare services, from February 2012 to September 2020. Through his career he has served on the boards of several other public and private companies in the food, engineering and financial services industries. In September 2011, Mr. Gray retired from his position as Chief Executive Officer of ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, a position he had held since November 2002. Having joined ICON in 1997, Mr. Gray had previously served as Group Chief Operating Officer. From 1983 to 1989, Mr. Gray served as senior financial officer at Elan Corporation plc, a pharmaceutical company.
Heather Ann McSharry brings a wide variety of operational expertise to Jazz’s board. With extensive experience with healthcare companies, Ms. McSharry also serves as a director for a food manufacturer, and previously for an international building materials company, and a home and hygiene consumer products company. This diversity enhances her ability to bring fresh perspectives while also demonstrating her ability to add value in varied situations.
Ms. McSharry has served as a member of our board of directors since May 2013 and was appointed as chairperson of our Nominating and Corporate Governance Committee in August 2017. Ms. McSharry currently serves as a non-executive director on the board of directors of the International Airlines Group (IAG). From 2006 to 2009, Ms. McSharry was Managing Director Ireland of Reckitt Benckiser, a multinational health, home and hygiene consumer products company. From 1989 to 2006, she held various positions at Boots Healthcare, a leading global consumer healthcare company, most recently as Managing Director of Boots Healthcare Ireland Limited. Ms. McSharry served on the board of directors of the Bank of Ireland from 2007 to 2011, where she helped the Bank navigate one of the world’s greatest financial crises. She also served on the boards of directors of the Industrial Development Agency in Ireland from 2010 to 2014, Uniphar plc from 2019 to 2020, CRH plc from 2012 to 2021 and Greencore Group plc from 2013 to 2021. Ms. McSharry holds a Bachelor of Commerce and a Master of Business Studies degree from University College Dublin.
Seamus Mulligan brings a diverse industry background and global business acumen. His professional experience includes working in specialty pharmaceuticals, drug delivery systems and with the National Pharmaceutical Council. His pharmaceutical and biopharmaceutical experience ranges from the development stage to commercialization. Mr. Mulligan earned a Bachelor and Masters of Science but set his career sights on exploring the intersection of healthcare and business.
Mr. Mulligan has served as a member of our board of directors since January 2012 and was a founder and principal investor of Azur Pharma. From 2014 until 2018, Mr. Mulligan served as Chairman and Chief Executive Officer of Adapt Pharma Ltd., a specialty pharmaceutical company, which was acquired in October 2018 by Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company, where Mr. Mulligan served on the board of directors until May 2020. From 2006 to April 2017, Mr. Mulligan served as Executive Chairman of Circ Pharma Limited and its subsidiaries, a pharmaceutical development stage group. Mr. Mulligan served as our Chief Business Officer, International Business Development from January 2012 until February 2013. Mr. Mulligan served as Azur Pharma’s Chairman and Chief Executive Officer and as a member of its board of directors from 2005 until January 2012. From 1984 until 2004, he held various positions with Elan Corporation, plc, a pharmaceutical company, most recently as Executive Vice President, Business and Corporate Development, and prior to that position, held the roles of President of Elan Pharmaceutical Technologies, the drug delivery division of Elan Corporation, plc, Executive Vice President, Pharmaceutical Operations, Vice President, U.S. Operations and Vice President, Product Development. He served as a member of the board of directors of the U.S. National Pharmaceutical Council until 2004. Mr. Mulligan received a B.Sc (Pharm) and M.Sc from Trinity College Dublin.
Kenneth W. O’Keefe brings an exceptional business analytics mindset along with corporate development and financial expertise to Jazz’s board. During his 24 year service as the founder of the Beecken Petty O’Keefe & Company private equity firm, Mr. O’Keefe has developed a keen business savvy and provides a diverse perspective to the pharmaceutical space.
Mr. O’Keefe has served as a member of our board of directors since 2004. Since January 2018, he has been Managing Director of Beecken Petty O’Keefe & Company, a private equity firm, which he co-founded. From November 2015 to January 2018, he was Chief Executive Officer, from January 2011 to November 2015, he was Managing Partner, and from 1997 to January 2011, he was Managing Director, of Beecken Petty O’Keefe & Company. He serves on the boards of several privately-held healthcare companies and numerous charitable and civic boards. He received a B.A. from Northwestern University and an M.B.A. from the University of Chicago.
Anne O’Riordan brings a global perspective to Jazz, with experience spanning careers in Asia, Europe and North America. She has focused specifically on strategic client development, market entry and business transformation for life sciences clients, and has significant expertise implementing digital strategies. Ms. O’Riordan excels at developing strategic client relationships and serves on the American Chamber of Commerce in Hong Kong, adding impressive business experience to her life sciences background.
Ms. O’Riordan has served as a member of our board of directors since February 2019. Since June 2019, Ms. O’Riordan has served as Group Director of Digital of Jardine Matheson Limited, an Asian conglomerate headquartered in Hong Kong, where she also serves on the board of directors. From 1990 to March 2019, Ms. O’Riordan held various leadership positions in the life sciences industry group in each of the operating units of Accenture (formerly Andersen Consulting) in North America, Europe and Asia Pacific. She most recently served as Global Industry Senior Managing Director of Accenture’s Life Sciences Business from 2012 to 2019. Between 2008 and 2012, Ms. O'Riordan led Accenture's life sciences practice in Asia Pacific. Prior to that, she led Accenture's European health and life sciences business, working with clients across Europe on significant regional transformation initiatives. She also spent nine years in North America working with pharmaceutical and medical products clients. She currently serves on the board of governors of the American Chamber of Commerce in Hong Kong, or AmCham Hong Kong, where she serves as the Treasurer and the board liaison for the Healthcare Committee. She is also a long-standing member of the Women of Influence Committee of AmCham Hong Kong as well as a member of The Women’s Foundation and the 30% Club. Ms. O'Riordan received a B.Sc in Biotechnology from Dublin City University as well as a postgraduate diploma in Financial Accounting and MIS from the National University of Ireland, Galway.
Norbert G. Riedel has a wide range of experience in everything from oncology and therapeutic proteins, to biopharmaceutical and biotechnological development. Dr. Riedel’s resume boasts global cultural literacy, as he has studied, taught and worked in Europe as well as North America. Having previously led a company through the IPO process, Dr. Riedel has intimate knowledge of business development and a keen eye for growth opportunities, and extensive experience managing talent and human capital management matters.
Dr. Riedel has served as a member of our board of directors since May 2013 and was appointed chairperson of our Compensation Committee in August 2013. Dr. Riedel has served as Chief Executive Officer of Aptinyx, Inc. since September 2015 and served as President from September 2015 to December 2020. Aptinyx, Inc. is a biopharmaceutical company spun out of its predecessor company, Naurex, Inc., where Dr. Riedel served as Chief Executive Officer and President from January 2014 to September 2015.
From 2001 to 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017. Dr. Riedel currently serves on the boards of directors of Aptinyx, Inc., Cerevel Therapeutics, a biopharmaceutical company, Eton Pharmaceuticals, Inc., a development stage pharmaceutical company, where he also serves as Chairman of the board, and the Illinois Biotechnology Industry Organization. Dr. Riedel is also a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University’s Feinberg School of Medicine. Dr. Riedel holds a Diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.
Elmar Schnee brings a diversity of pharmaceutical experience to Jazz’s Board given his work in specialty pharmaceuticals and biopharmaceuticals in addition to his previous work in neuro-technology. His prior business experience has given him global exposure and allowed him to hone his skills in strategy, business development and marketing.
Mr. Schnee has served as a member of our board of directors since August 2014 and previously served as a director of Gentium S.p.A. (now a subsidiary of Jazz Pharmaceuticals plc) from May 2012 until April 2014. Mr. Schnee has served as Chairman of the boards of Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, since April 2017; Calliditas Therapeutics AB, a specialty pharmaceutical company, since May 2019; and Genkyotex, a biopharmaceutical company, since November 2020. In addition, he serves on the boards of directors of several privately-held life sciences companies and, since January 2020, has been serving as the Chairman of Advanz Pharma Corp., a global pharmaceutical company. From June 2016 to December 2019, he served as a management advisor to MindMaze SA, a neuro-technology company, where he also served as Chief Operating Officer from June 2016 to April 2017. From November 2013 to August 2015, Mr. Schnee served as a non-executive director of Cardiorentis Ltd., a biopharmaceutical company, where he served as Chairman and Chief Executive Officer from October 2011 until November 2013. From 2003 to 2011, Mr. Schnee held various positions in senior management at Merck KGaA, a global pharmaceutical and chemical group. In November 2005, Mr. Schnee was appointed as Deputy Member of the Executive Board responsible for the global pharmaceuticals business. In 2006, he was appointed as a member of the Executive Board and General Partner of Merck KGaA, with responsibility for global pharmaceutical activities, and served in this position until 2011. Prior to Merck KGaA, Mr. Schnee held senior positions in strategy, business development and marketing at UCB SA, Sanofi-Synthélabo SA, Migliara/Kaplan Associates, Inc. and Fisons Pharmaceuticals PLC. From June 2016 until May 2019, he served on the board of directors of Stallergenes-Greer plc. Mr. Schnee holds both a bachelor’s degree in marketing and a master’s degree in marketing and general management from the Swiss Institute of Business Administration in Zurich.
Mark D. Smith, M.D. has an impressive background that marries the worlds of active medical practice and business development. A practicing physician and professor, Dr. Smith also has experience working for a variety of health focused companies both public and private. Additionally, Dr. Smith allocates part of his time for nonprofit organizations and a health policy foundation. Dr. Smith believes that increasing the role of value-based payment is the most exciting current development in medicine, as the system requires an innovative overhaul.
Dr. Smith has served as a member of our board of directors since December 2020. Dr. Smith is a practicing physician and professor of clinical medicine at the University of California at San Francisco, where he has served since 1994. He also serves as a non-executive director on the boards of directors of two publicly-held companies, Teladoc Health, Inc., a telemedicine and virtual healthcare company which recently merged with Livongo, and Phreesia, Inc., a healthcare software company. Dr. Smith also serves on the boards of directors of The Commonwealth Fund, a private health policy foundation, and the Institute for Health Care Improvement, an independent nonprofit organization pursuing quality improvement in health care around the world. From 1996 to 2013, Dr. Smith was the founding President and Chief Executive Officer of the California HealthCare Foundation, an independent nonprofit philanthropy organization. From 1991 to 1996, he served as Executive Vice President at the Henry J. Kaiser Family Foundation. Dr. Smith received a B.A. from Harvard College, an M.D. from the University of North Carolina at Chapel Hill and an M.B.A. from The Wharton School at the University of Pennsylvania.
Catherine A. Sohn, Pharm.D. brings over 30 years of life sciences, biopharmaceutical and business development experience to Jazz’s Board. Her business development expertise has enhanced her biopharmaceutical background as she has worked in various elements of biopharmaceutical development down to the clinical stage.
Dr. Sohn has served as a member of our board of directors since July 2012. Dr. Sohn is an independent director on the boards of directors of three additional public companies: Axcella Health Inc., a biotechnology company, Landec Corporation, a life sciences company and Rubius Therapeutics, a biotechnology company. She also serves as Chairperson of the board of BioEclipse Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company. From January 2014 to May 2017, Dr. Sohn served as an independent director on the board of directors of Neuralstem, Inc., a publicly-traded life sciences company. From 1998 to 2010, she was Senior Vice President, Worldwide Business Development and Strategic Alliances at GlaxoSmithKline Consumer Healthcare. From 1994 to 1998, she was Vice President, Worldwide Strategic Product Development at SmithKline Beecham Pharmaceuticals plc in the pharmaceutical division. From 1982 to 1994, she held a series of positions in Medical Affairs, Pharmaceutical Business Development and U.S. Product Marketing at SmithKline Beecham Pharmaceuticals plc and its predecessor, Smith, Kline & French. Dr. Sohn holds the position of Adjunct Professor at the University of California, San Francisco. She received a Doctor of Pharmacy from the University of California, San Francisco, School of Pharmacy and a Certificate of Professional Development from the Wharton School at the University of Pennsylvania. Dr. Sohn was named Woman of the Year by the Healthcare Businesswomen's Association (2003), Distinguished Alumnus of the Year by the University of California, San Francisco (2000), the Frank Barnes Mentoring Award from the Licensing Executive Society, and is a National Association of Corporate Directors (NACD) Board Leadership Fellow.
Rick E Winningham brings his impressive industry knowledge and business acumen to Jazz’s Board. He is a member of Biotechnology Industry Organization’s board of directors and serves on the Health Section Governing Board Standing Committee on Reimbursement, has served as a director for a state-wide trade association as well as having been president of a major Oncology/Immunology/Oncology Therapeutics network. Additionally, the combination of Mr. Winningham’s biopharmaceutical background with his business experience makes him a versatile and insightful member of our Board.
Mr. Winningham has served as a member of our board of directors since May 2010. In May 2014, Mr. Winningham was appointed as Lead Independent Director of our board of directors. Mr. Winningham has served as Chairman of the board of directors of Theravance Biopharma, Inc., a biopharmaceutical company, since July 2013. He has served as Chief Executive Officer of Theravance Biopharma, Inc. since its spin-off from Innoviva, Inc. in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Innoviva, Inc., where he also served as Chairman of the Board of Directors from April 2010 to October 2014. He serves as Chairman of Retrotope, Inc., a private biotechnology company focused on cell degeneration. From 1997 to 2001, he served as President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000 to 2001, as President of Global Marketing. He previously served as a member of the board of directors of OncoMed Pharmaceuticals, Inc. from June 2015 until the company’s merger with Mereo BioPharma Group plc in April 2019. He also served as a member of the board of directors of the California Healthcare Institute, or CHI, from November 2011 to March 2015 and served as its Chairman from January 2014 until CHI merged with Bay Area Bioscience Association to become the California Life Sciences Association, or CLSA, in March 2015. Mr. Winningham is on the board of directors of CLSA, and served as its Chairman from March 2015 until November 2015. He also serves on the board of directors of Biotechnology Innovation Organization or BIO since 2014, where he serves on its Health Section Governing Board. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.
Our Board of Directors has three standing committees: an Audit Committee, a Compensation & Management Development Committee and a Nominating & Corporate Governance Committee. The following table provides membership information for each committee.
|Audit Committee||Compensation & Management Development Committee||Nominating & Corporate Governance Committee|
|Paul L. Berns|
|Jennifer E. Cook|
|Patrick G. Enright|
|Heather Ann McSharry|
|Kenneth W. O’Keefe|
|Norbert G. Riedel|
|Mark D. Smith|
|Catherine A. Sohn|
|Rick E Winningham*|
*Lead Independent Director.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.